Novel Gain-of-Function Mutation in Stat1 Sumoylation Site Leads to CMC/CID Phenotype Responsive to Ruxolitinib

MLA

Kimberley Gilmour, et al. “Novel Gain-of-Function Mutation in Stat1 Sumoylation Site Leads to CMC/CID Phenotype Responsive to Ruxolitinib.” Journal of Clinical Immunology, vol. 39, no. 8, Feb. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d7816ab08296d16eb8df347ccdc993b5&authtype=sso&custid=ns315887.

APA

Kimberley Gilmour, T Mohanadas, Andrew J. Cant, AD Rowan, Mary Slatter, S Loughlin, Al, S. T., Shahnaz Bibi, Angela Grainger, Desa Lilic, F Gothe, Timothy Ronan Leahy, & Sophie Hambleton. (2019). Novel Gain-of-Function Mutation in Stat1 Sumoylation Site Leads to CMC/CID Phenotype Responsive to Ruxolitinib. Journal of Clinical Immunology, 39(8).

Chicago

Kimberley Gilmour, T Mohanadas, Andrew J. Cant, AD Rowan, Mary Slatter, S Loughlin, Shehri, T Al, et al. 2019. “Novel Gain-of-Function Mutation in Stat1 Sumoylation Site Leads to CMC/CID Phenotype Responsive to Ruxolitinib.” Journal of Clinical Immunology 39 (8). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d7816ab08296d16eb8df347ccdc993b5&authtype=sso&custid=ns315887.